Category: 54856-23-4

Gohil, Vishal M. published the artcileNutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis, Recommanded Product: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, the publication is Nature Biotechnology (2010), 28(3), 249-255, database is CAplus and MEDLINE.

Most cells have the inherent capacity to shift their reliance on glycolysis relative to oxidative metabolism, and studies in model systems have shown that targeting such shifts may be useful in treating or preventing a variety of diseases ranging from cancer to ischemic injury. However, we currently have a limited number of mechanistically distinct classes of drugs that alter the relative activities of these two pathways. We screen for such compounds by scoring the ability of >3500 small mols. to selectively impair growth and viability of human fibroblasts in media containing either galactose or glucose as the sole sugar source. We identify several clin. used drugs never linked to energy metabolism, including the antiemetic meclizine, which attenuates mitochondrial respiration through a mechanism distinct from that of canonical inhibitors. We further show that meclizine pretreatment confers cardioprotection and neuroprotection against ischemia-reperfusion injury in murine models. Nutrient-sensitized screening may provide a useful framework for understanding gene function and drug action within the context of energy metabolism

Nature Biotechnology published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Recommanded Product: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Cirek, Zdenek published the artcileEfficacy and tolerability of a fixed combination of cinnarizine and dimenhydrinate versus betahistine in the treatment of otogenic vertigo: A double-blind, randomised clinical study, HPLC of Formula: 54856-23-4, the publication is Clinical Drug Investigation (2005), 25(6), 377-389, database is CAplus and MEDLINE.

Introduction: Peripheral vestibular disorders frequently lead to the manifestation of symptoms of vertigo. The objective of this study was to compare the efficacy and tolerability of a fixed combination of cinnarizine 20mg and dimenhydrinate 40mg per tablet with betahistine (betahistine dimesylate) 12mg per tablet in the treatment of patients with otogenic vertigo. Patients and methods: Sixty-one patients with vertigo due to peripheral vestibular disorders (otogenic vertigo) participated in this prospective, double-blind, comparative, single-center study. Patients were randomly allocated to treatment with betahistine 12mg or the fixed combination of cinnarizine 20mg and dimenhydrinate 40mg, both treatments given three times daily for 4 wk. Efficacy was determined by patients’ assessments of vertigo symptoms after 1 and 4 wk of treatment using a visual analog scale to determine a ‘mean vertigo score’. Results: Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores compared with the reference therapy betahistine. This was evident as early as 1 wk after the onset of treatment (p = 0.002). Over 4 wk of therapy, the fixed combination decreased the intensity of vertigo symptoms about 2-fold compared with betahistine (p = 0.001). Furthermore, reductions in symptoms typically associated with vertigo were more pronounced (p = 0.009) in the fixed-combination group compared with the betahistine group after 4 wk of treatment. No serious adverse events were reported in either treatment group. Tolerability of the fixed combination was judged as ‘very good’ by 97% (betahistine 90%) and as ‘good’ by 3% (betahistine 10%) of patients. Conclusion: The fixed combination of cinnarizine and dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with otogenic vertigo. It proved to be statistically more efficient in reducing vertigo than the widely used betahistine. Therefore, the fixed combination of cinnarizine and dimenhydrinate may be considered a first-line treatment option for the treatment of otogenic vertigo.

Clinical Drug Investigation published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, HPLC of Formula: 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Mizugaki, Michinao published the artcileExtra-weak chemiluminescence of drugs. I. Extra-weak chemiluminescence of tablets and capsules, Name: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, the publication is Yakugaku Zasshi (1985), 105(4), 401-6, database is CAplus and MEDLINE.

The measurement of extra-weak chemiluminescence of 139 tablets and capsules was carried out with single photoelectron counting apparatus The tablets and capsules tested showed chemiluminescence values of 0 to 1380 counts/10 s, 0 to 10,800 counts/10 s and 37 to 245,000 counts/10 s, at 20, 50 and 80°, resp. Among the drugs tested in this report, imipramine, indole, and phenothiazine derivatives showed high chemiluminescence values.

Yakugaku Zasshi published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Name: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Kawabata, Atsuhiko published the artcileEffects of anti-vertigo drugs on medial vestibular nucleus neurons activated by horizontal rotation, Recommanded Product: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, the publication is Japanese Journal of Pharmacology (1991), 55(1), 101-6, database is CAplus and MEDLINE.

The effects of anti-vertigo drugs on the brain medial vestibular nucleus (MVN) neurons were examined to assess the site and mode of action using cats anesthetized with α-chloralose. Single neuron activity in the MVN was extracellularly recorded using a silver wire microelectrode filled with diphenhydramine, diphenidol, betahistine, glutamate, or NaCl. Type I of the MVN neurons were identified according to the responses obtained when the animal placed on a turn-table was rotated sinusoidally. The drug effects were examined on type I neurons which received impulses primarily from the labyrinth and sent them to the oculomotor nuclei. The microiontophoretic application of diphenhydramine, diphenidol, and betahistine inhibited the rotation-induced firing of type I MVN neurons. Diphenhydramine and diphenidol were more potent than betahistine. These drugs act directly on MVN neurons and reduce the responsiveness to rotatory stimulation.

Japanese Journal of Pharmacology published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Recommanded Product: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Wei, Ningyi published the artcileImprovement and suggestion on the problems existing in the betahistine mesilate monograph, SDS of cas: 54856-23-4, the publication is Zhongguo Yaopin Biaozhun (2011), 12(5), 384-386, database is CAplus.

A method for determination of water in betahistine mesilate that was of hygroscopicity and thermal instability was established. HPLC, TLC, DSC purity, and hygroscopicity under varying relative humidity conditions were determined Loss on drying influenced on purity of betahistine mesilate. Determination of water by Karl Fischer should be instead of loss on drying in vacuum at 70 degree method. Loss on drying makes betahistine mesilate degraded. The Karl Fischer method is simple, accurate, and suitable for determination of water.

Zhongguo Yaopin Biaozhun published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C7H13NO2, SDS of cas: 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Safarudin published the artcileEvaluation of lipid profile in patients with cardiovascular diseases receiving simvastatin in Palu Indonesia, Related Products of pyridine-derivatives, the publication is Journal of Pharmacy and Nutrition Sciences (2018), 8(4), 199-204, database is CAplus.

Cardiovascular diseases (CVDs) are the leading cause of death worldwide which results from the impaired function of the heart and blood vessels. The most common CVDs are coronary heart and stroke. The main clin. manifestation of these diseases is the formation of atherosclerosis which is associated with the change of blood lipid levels. Simvastatin is widely used in patients with impaired lipid levels in the blood. The study was a descriptive research with a retrospective approach on medical record data (n = 64) taken from Palu City, Central Sulawesi, Indonesia. The variables included in this study were gender, age, diagnosis, co-medication, lipid profile including total cholesterol, LDL, triglycerides, and HDL in patients with CVDs receiving simvastatin. In the study, sixty-four patients of CVDs met the inclusion and exclusion criteria. This study suggested that simvastatin achieved to normalize the blood lipid levels, including total cholesterol in forty-four patients (68.75%), LDL in forty-nine patients (80.3%), triglycerides in fifty-nine patients (92.19%), and HDL in fifty-two patients (81.25%). The use of simvastatin in patients with CVDs managed to lower total cholesterol, LDL, and triglycerides, as well as increase the HDL level.

Journal of Pharmacy and Nutrition Sciences published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Related Products of pyridine-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Nishide, Shigenori published the artcileImproved determination of betahistine mesylate, Synthetic Route of 54856-23-4, the publication is Yakugaku Zasshi (1983), 103(11), 1180-4, database is CAplus and MEDLINE.

An improved method for the determination of betahistine mesylate (I) [54856-23-4] in tablets was developed by the use of UV spectrophotometry at 260 nm. The determination of in aqueous solutions were affected by pH and temperature The measurement of the mesylate in 0.1 N sulfuric acid instead of water produced more accurate results.

Yakugaku Zasshi published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Synthetic Route of 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Yang, Shaomei published the artcileDetermination of betahistine mesylate in tablets by ion chromatography, Formula: C10H20N2O6S2, the publication is Huagong Jishu Yu Kaifa (2011), 40(4), 27-29, database is CAplus.

The sulfur in the mol. structure of betahistine mesylate sample was converted into its oxides via combustion and further absorption by an absorbing solution to become sulfate. The sulfate in the solution was determined by ion chromatog. The amount of betahistine mesylate was derived from its stoichiometric relationship with sulfur. The calibration curve of sulfur was linear in the concentration range of 0.02-60 μg/mL. The average recovery was 98.8% with RSD of 0.15%. The method was simple, accurate and reproducible, and it could be used for the quality control of betahistine mesylate tablets.

Huagong Jishu Yu Kaifa published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C7H12ClNO, Formula: C10H20N2O6S2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Beraki, Simret published the artcileA pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke, Category: pyridine-derivatives, the publication is PLoS One (2013), 8(7), e69233, database is CAplus and MEDLINE.

With the availability and ease of small mol. production and design continuing to improve, robust, high-throughput methods for screening are increasingly necessary to find pharmacol. relevant compounds amongst the masses of potential candidates. Here, we demonstrate that a primary oxygen glucose deprivation assay in primary cortical neurons followed by secondary assays (i.e. post-treatment protocol in organotypic hippocampal slice cultures and cortical neurons) can be used as a robust screen to identify neuroprotective compounds with potential therapeutic efficacy. In our screen about 50% of the compounds in a library of pharmacol. active compounds displayed some degree of neuroprotective activity if tested in a pre-treatment toxicity assay but just a few of these compounds, including Carbenoxolone, remained active when tested in a post-treatment protocol. When further examined, Carbenoxolone also led to a significant reduction in infarction size and neuronal damage in the ischemic penumbra when administered six hours post middle cerebral artery occlusion in rats. Pharmacol. testing of Carbenoxolone-related compounds, acting by inhibition of 11-β-hydroxysteroid dehydrogenase-1 (11β-HSD1), gave rise to similarly potent in vivo neuroprotection. This indicates that the increase of intracellular glucocorticoid levels mediated by 11β-HSD1 may be involved in the mechanism that exacerbates ischemic neuronal cell death and inhibiting this enzyme could have potential therapeutic value for neuroprotective therapies in ischemic stroke and other neurodegenerative disorders associated with neuronal injury.

PLoS One published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Category: pyridine-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Ijuin, Kazushige published the artcileClassification of drugs according to drug supply stochastic properties at a pharmacy, Safety of N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, the publication is Iryo Yakugaku (2006), 32(6), 489-496, database is CAplus.

Eighty-one prescription drugs were divided into three groups according to the strength of the auto-correlation (strong, weak or none) of daily variations in the drug supply amounts at a pharmacy. The power spectral d. and autocorrelation function were used as an indicator for the classification. Sixty-four drugs fell into the no auto-correlation group, 15 drugs into the weak auto-correlation group and 2 drugs into the strong auto-correlation group. Interestingly, our grouping using auto-correlation as a criterion was consistent with the target-oriented classification (standard commodity classification of Japan).

Iryo Yakugaku published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Safety of N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem